PepGen Inc. (NASDAQ:PEPG) Holdings Lifted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its position in shares of PepGen Inc. (NASDAQ:PEPG) by 26.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,102 shares of the company’s stock after acquiring an additional 11,870 shares during the period. Dimensional Fund Advisors LP owned about 0.18% of PepGen worth $216,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PEPG. China Universal Asset Management Co. Ltd. acquired a new position in shares of PepGen during the 4th quarter worth about $26,000. Barclays PLC grew its holdings in shares of PepGen by 318.7% in the 3rd quarter. Barclays PLC now owns 21,971 shares of the company’s stock worth $189,000 after purchasing an additional 16,723 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of PepGen by 289.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 26,611 shares of the company’s stock worth $228,000 after purchasing an additional 19,786 shares in the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.

Insider Transactions at PepGen

In other PepGen news, CEO James G. Mcarthur purchased 41,500 shares of the business’s stock in a transaction on Tuesday, April 8th. The shares were purchased at an average cost of $1.15 per share, with a total value of $47,725.00. Following the transaction, the chief executive officer now directly owns 103,913 shares of the company’s stock, valued at $119,499.95. This represents a 66.49% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on PepGen from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 9th.

PepGen Stock Performance

Shares of PepGen stock opened at $1.54 on Friday. PepGen Inc. has a 52 week low of $0.88 and a 52 week high of $19.30. The firm has a fifty day moving average of $1.52 and a two-hundred day moving average of $2.78. The stock has a market capitalization of $50.39 million, a price-to-earnings ratio of -0.52 and a beta of 1.39.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.20). As a group, research analysts forecast that PepGen Inc. will post -2.73 EPS for the current fiscal year.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.